Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Novel therapies for AD that avoid immunosuppression and potential carcinogensis are needed.
EpiCeram™ , a topical cream, represents a novel class of therapy for skin disorders that does
not contain corticosteroids or other anti-inflammatory drugs. The objective of the present
study is to demonstrate the safety and efficacy of EpiCeram ™ in the treatment of moderate to
severe atopic dermatitis as compared to mid-strength topical steroid cream following twice
daily dosing for four weeks in pediatric patients with AD. The potential benefit to patients
lies in the potential for EpiCeram ™ to provide restoration of the normal skin barrier as
shown in previous studies and eliminate or reduce the requirement for supplemental topical
steroid administration.